To determine the incidence of sickle cell disorders (SCDs) and the feasibility of a neonatal screening programme in Ouagadougou. Methods: During 2000 and 2004 , 2341 cord blood samples obtained in five maternity hospitals in Ouagadougou were screened for SCDs using an isoelectric focusing technique. The feasibility of a neonatal screening programme was evaluated. Results: The incidence of SCD was 1:57; 14 neonates were homozygous for haemoglobin (Hb)S and 27 were compound heterozygotes for HbSC. Thirty-two neonates were homozygous for HbC. The incidence of the HbC trait was 1:6; incidence of the HbS trait was 1:14. A centralized laboratory for neonatal screening of SCDs was established. Conclusions: SCDs should be considered a major public health problem in Ouagadougou. A neonatal screening programme should be implemented, but to be effective it requires strategies adapted to the local situation.
INTRODUCTION
I n West Africa, the incidence of sickle cell disorders (SCDs) is relatively high and constitutes a major public health problem. 1, 2 With improvements in health and nutrition conditions, West African infant mortality declines and genetic disorders emerge as important causes of deaths and chronic disabilities. In Burkina Faso, the gene frequencies for haemoglobin (Hb)S and HbC in adults were estimated to be around 0.04 and 0.10, respectively. 3 The geographical distribution of SCDs correlates with areas where Plasmodium falciparum is historically endemic, as they are naturally selected for by malaria. It is now recognized that HbS and HbC are associated with a reduced risk of severe malaria. 4 Nevertheless, if there is a limited sickle cell pathology associated with HbAC, HbAS and HbCC phenotypes, there is a severe disadvantage to carriers of the HbSS and HbSC phenotypes.
Neonatal screening programmes for SCDs have been implemented in many countries in the world using simple methods for mass screening. If associated with a clinical care programme, they have proven to be an important opportunity to decrease mortality and morbidity in these countries. 5, 6 The objective of this study was to determine the frequency of these disorders in a newborn population, as well as the feasibility of implementing a neonatal screening programme in Ouagadougou.
MATERIAL AND METHODS Cord blood samples
Neonatal screening for SCD was conducted over three different periods: three months in 2000, two months in 2003 and three months in 2004. Blood samples were collected on ethylenediamine tetra-acetic acid (EDTA) from neonates born in five Ouagadougou maternity hospitals (Patte d'oie, Yennenga, Pogbi and Goughin sectors 8 and 9). The ethnicity and birth weight of the neonates were reported. No selective criteria were applied and none of the samples were excluded.
Screening test for sickle cell disease
All cord blood samples were analysed using an isoelectric focusing (IEF) technique on agar gels, as previously described (Isolab Inc., Akron, OH, USA). 7
Identification and quantification of variants detected
In the last period of neonatal screening (three months in 2004), all samples with suspected abnormal Hb fractions at IEF were further analysed by high-performance liquid chromatography (HPLC) using the b-thalassaemia short programme kit on a BioRad Variant (BioRad, Hercules, CA, USA) and capillary zone electrophoresis (CZE) using the HbA1c-CE kit (ANALIS, Namur, Belgium), as previously described. 8 
Haematological tests
In the last period of neonatal screening (three months in 2004), haematological parameters were automatically determined using ABX pentra 60C þ (ABX Diagnostics, Irvine, CA, USA). The parameters included Hb level, haematocrit, mean corpuscular volume (MCV), mean corpuscular Hb (MCH), mean corpuscular Hb concentration (MCHC), red cell, white cell and platelet counts.
Reporting results
When possible, parents of every newborn with a severe form of SCD were informed immediately and a repeat sample was requested in order to confirm the suspected diagnosis. Simple heterozygotes were not reported.
Statistical analysis
To compare between a-thalassaemic and non-a-thalassaemic neonates, statistical analysis was performed using a nonparametric Mann-Whitney test.
RESULTS Newborns
During the years 2000, 2003 and 2004, 2341 newborns were screened. The newborns were derived from various ethnic groups: 59.2% Mossi, 14.3% Gouroussi, 9.4% Bissa, 6.7% Gourmatche, 5.8% miscellaneous and 4.6% foreigners. The mean birth weight was 2808 g (range 800-4140 g).
Screening for sickle cell disease
Of the 2341 newborns screened, 41 cases of SCD were suspected: 27 newborns were thought to be compound heterozygotes for HbS and HbC, and 14 to be homozygotes for HbS (Table 1 ). The incidence of suspected SCDs in this population was 1:57 (41/2341).
Screening for other significant haemoglobinopathies
Of the 2341 newborns screened, 32 cases of HbC disease (HbCC) were suspected. The incidence of suspected HbC disease in this population was 1:73 (32/2341; Table 1 ). None of the newborns was suspected of having b-thalassaemia major (b1/b1).
Detection of heterozygotes for Hb variants
Of the 2341 newborns screened, 569 newborns were suspected to be carriers of variant Hb. HbC, S, O and E were suspected in, respectively, 395, 171, one and one samples. In one case, a fetal Hb variant was suspected. From the whole data, the incidences for HbC and HbS were estimated at 1:5 (453/2341) and 1:11 (212/2341), respectively (Table 1 ).
Identification and quantification of the variants detected
Of the 538 newborns screened in 2004, all the results suspected by IEF were confirmed by HPLC and CZE except for one variant: a suspected HbC was in fact an HbO Arab . Quantification of HbA, HbC and HbS has allowed confirmation of a heterozygous state and not a compound heterozygous b-thalassaemia þ /Hb variant state. The results of the newborns suspected to be homozygous for HbS or HbC were not confirmed by molecular analysis.
Screening for a-thalassaemia
Of the 538 newborns screened in 2004, IEF was performed without delay and Hb Bart's was observed in 40 newborns (1:13): 32 of those were homozygous for HbA and eight were heterozygous for HbC. Neonates without anaemia (Hb 412.5 g/dL) and with a birth weight X2500 g were divided into two groups, with (n ¼ 203) and without (n ¼ 27) Hb Bart's. MCV and MCH were significantly different between the two groups ( Table 2 ).
Reporting of SCD newborns
Of the 41 newborns suspected of having an SCD, five families received information. The results were explained to them, and appropriate education, counselling and treatment were made available.
DISCUSSION
This systematic neonatal screening for haemoglobinopathies confirmed other reports on the high incidence of abnormal Hbs in Ouagadougou, Burkina Faso. 3, 9, 10 In our study, we found that the incidence of Hb variants was 1:4 (642/2341), with a predominance of HbC (1:5; 454/2341) over HbS (1:11; 212/2341). These incidence data are higher than those reported by Simpore et al. in a population of 6619 students from local schools in Ouagadougou, which showed an incidence of 1:9 and 1:19 for HbC and HbS, respectively. This could be related to a difference in the ethnic groups tested, since in our study 40.8% were of ethnic groups other than Mossi and Rimaibe, for which the highest incidences of HbC and HbS were reported by Modiano et al. 3 As expected, HbC was the most frequent Hb variant observed in the newborns tested. Population studies and genetic evidence showed that the b C -globin gene mutation occurred among ethnic groups in Burkina Faso and its higher frequency was reached in Central West Africa. 10 a-Thalassaemia in the African population is virtually always of the -a 3.7 type, and its incidence has been reported to be around 1:6 in Burkina Faso. Elevated a þ -thalassaemia frequency has also been reported in sickle cell anaemia patients in Burkina Faso. 11 Detection of Hb Bart's in cord blood is an indication that the newborn is a carrier of a-thalassaemia. Unfortunately, underestimation (by up to 15%) of the number of newborns with the genotype Àa/aa has been reported when cord blood Hb Bart's is used to estimate the a þ -thalassemia gene frequency. 12 Despite an attempt to exclude the false-negative (anaemia) and falsepositive (low birth weight) results, this might explain our lower incidence (1:13) of suspected a þ -thalassaemia. Neonatal screening programmes for SCDs aim to identify the newborns who have an SCD and who can benefit from early prophylactic penicillin, the administration of antipneumococcal vaccination, and education of the parents for comprehensive care. 5 Such a programme can be implemented where it is needed, but it must be adapted to the local situation. 13 For example, it must be remembered that antipneumococcal vaccination is not available in many African countries.
It has been reported that neonatal screening is costeffective if it covers over 40,000 births per year, and that IEF and HPLC are very similar in terms of average cost per test. 14 Ouagadougou's annual birth rate being around 40,000, neonatal screening for SCD started in one central laboratory of Ouagadougou using IEF could be cost-effective. The prices of consumables could also be reduced by using filter papers to collect samples and by using homemade IEF agarose gels. Nevertheless, the first problems encountered in our pilot study were the financial support and the involvement of different teams -gynaecologists, paediatricians, nurses and central laboratory staff -needed to apply the screening programme. An external financial support (CUD) was obtained for a project described by the central laboratory staff. This is why the SCD programme was interrupted many times. Indeed, to ensure the continuation of screening, all the different local health authorities must be involved in its financial support.
The first aim of the neonatal screening was to gather epidemiological data, but the reporting of homozygotes and compound heterozygotes was obvious. Nevertheless, even if the neonatal screening was performed using cord blood and despite the short time taken to obtain the screening result, the mother and her baby had often left the hospital (usually two days post delivery). We frequently face a problem regarding mothers changing their addresses in the postpartum period. It was therefore often impossible to give and explain the test results. We believe that a strategy must be adapted to this local situation. At least two strategies could be tested. One option is to use the mandatory antenatal screening visits to inform all the women carrying a sickle cell or HbC trait that her baby will be tested at birth and to remind the mothers, using an adapted form of counselling at subsequent antenatal visits, of the importance of knowing the Hb phenotype of her baby. This strategy has been adopted in Cotonou, Benin, where it was shown that 82% (770/973) of the mothers came back to learn the Hb phenotype of their babies. 15 Another strategy could be to use the child vaccination programme. At the first visit, a sample could be obtained for SCD screening and counselling could be given to the mother. At the next visit, the result could be available and explained to the mother. These two strategies will both be tested in Ouagadougou.
SCDs are encountered with high frequency in Ouagadougou. As a consequence, neonatal screening for these disorders should be implemented. Nevertheless, this study raises several issues regarding the successful implementation of a neonatal screening programme in Ouagadougou. If screening laboratory centralization is achieved, strategies should be applied to successfully communicate the results and their meaning to clinicians and families through education. There also needs to be co-ordination and funding adapted to the local situation.
